Novaliq and Laboratoires Théa Announce Partnership and EU Approval for Vevizye® (Ciclosporin 0.1% Eye Drops Solution)

Contributed by: Business Wire

Logo

Tags

Biotechnology

Health

Pharmaceutical

Optical

Clinical Trials

Laboratoires Théa

More Like This

Novaliq Receives Positive CHMP Opinion for Vevizye® in Dry Eye Disease (Graphic: Business Wire)

Novaliq Receives Positive CHMP Opinion for Vevizye® in Dry Eye Disease

Théa Opens a New Chapter in Retinal Diseases

Heng Qin® is the first and only drug approved to treat DED associated with MGD and will be available to patients in China in the coming months.

Breakthrough in Ophthalmology! Hengrui’s Heng Qin® (Perfluorohexyloctane Eye Drops) Approved as First Treatment for Dry Eye Disease Associated with MGD

Nordic Pharma Group B.V. Through Its Subsidiary Amring Pharmaceuticals Inc., Completes Acquisition of Visant Medical to Launch Novel Therapy for Dry Eye Disease in the United States

LumiThera Obtains FDA Authorization of Valeda Treatment for Dry AMD Patients to Improve Vision

PR Newswire associated0

NTC presents positive results from Phase II Mirakle study evaluating an innovative drug for bacterial conjunctivitis

PR Newswire associated0

NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC. (U.S.), ANNOUNCES LACRIFILL® CANALICULAR GEL INCLUSION IN NEW DRY EYE WORKSHOP (DEWS) III MANAGEMENT AND THERAPY REPORT FROM THE TEAR FILM AND OCULAR SURFACE SOCIETY (TFOS) IN AMERICAN JOURNAL OF OPHTHALMOLOGY

LumiThera’s LIGHTSITE IIIB Extension Trial Topline Results Show Extended Vision Improvement in Dry AMD Subjects